Alder BioPharmaceuticals Company Profile (NASDAQ:ALDR)

About Alder BioPharmaceuticals (NASDAQ:ALDR)

Alder BioPharmaceuticals logoAlder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ALDR
  • CUSIP: N/A
  • Web: www.alderbio.com
Capitalization:
  • Market Cap: $778.71 million
  • Outstanding Shares: 67,713,000
Average Prices:
  • 50 Day Moving Avg: $11.22
  • 200 Day Moving Avg: $14.18
  • 52 Week Range: $8.60 - $34.30
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.88
  • P/E Growth: -0.09
Sales & Book Value:
  • Annual Revenue: $683,000.00
  • Price / Sales: 1,140.12
  • Book Value: $4.35 per share
  • Price / Book: 2.64
Profitability:
  • EBITDA: ($257,760,000.00)
  • Return on Equity: -78.68%
  • Return on Assets: -72.72%
Debt:
  • Current Ratio: 7.23%
  • Quick Ratio: 7.20%
Misc:
  • Average Volume: 1.30 million shs.
  • Beta: 2.62
  • Short Ratio: 3.45
 

Frequently Asked Questions for Alder BioPharmaceuticals (NASDAQ:ALDR)

What is Alder BioPharmaceuticals' stock symbol?

Alder BioPharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."

How were Alder BioPharmaceuticals' earnings last quarter?

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($1.48) earnings per share for the quarter, beating analysts' consensus estimates of ($1.67) by $0.19. The company had revenue of $0.68 million for the quarter. Alder BioPharmaceuticals's quarterly revenue was up 518.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.79) EPS. View Alder BioPharmaceuticals' Earnings History.

Where is Alder BioPharmaceuticals' stock going? Where will Alder BioPharmaceuticals' stock price be in 2017?

11 brokers have issued 1-year price objectives for Alder BioPharmaceuticals' stock. Their forecasts range from $11.00 to $51.00. On average, they expect Alder BioPharmaceuticals' stock price to reach $31.55 in the next year. View Analyst Ratings for Alder BioPharmaceuticals.

What are analysts saying about Alder BioPharmaceuticals stock?

Here are some recent quotes from research analysts about Alder BioPharmaceuticals stock:

  • 1. Mizuho analysts commented, "We received an email from Alder yesterday on its recap of the 18th Congress of the International Headache Society (IHC) meeting as it relates to eptinezumab. What we found as incremental data points are Alder’s interviews with practicing physicians on the advantages of eptinezumab. We believe the IV formulation for eptinezumab is a positive differentiation from other CGRP products in late stage development because of its reimbursement and potentially better compliance." (9/15/2017)
  • 2. According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (8/8/2017)
  • 3. Needham & Company LLC analysts commented, "Results from the ongoing pivotal Phase 3 PROMISE-1 trial in patients with frequent episodic migraines (FEM) are expected this month. In the context of positive Phase 3 FEM results from all competitor CGRP antibody programs (AMGN, LLY, TEVA), we think PROMISE-1’s primary endpoint will generally be in-line with the competition. However, we expect differentiation with key secondary endpoints (≥75% reduction in migraine days over weeks 1-12 and weeks 1-4), which we think will be important for commercial success. We maintain our view that there is room for multiple players in the migraine prophylaxis market, and we believe Alder shares remain underappreciated even in a scenario where PROMISE-1 data are positive but undifferentiated. Alder’s current EV (~$550M) reflects treatment of just ~63k patients with eptinezumab in 2027 in our model, or <1% of our estimated 7.1M prevention therapy candidates."" (6/9/2017)
  • 4. Aegis analysts commented, "We conducted an in-depth analysis of four late-stage monoclonal antibodies in development for migraine prevention – See table 1." (4/10/2017)

Who are some of Alder BioPharmaceuticals' key competitors?

Who are Alder BioPharmaceuticals' key executives?

Alder BioPharmaceuticals' management team includes the folowing people:

  • Stephen M. Dow, Independent Chairman of the Board
  • Randall C. Schatzman Ph.D., President, Chief Executive Officer, Director
  • Larry K. Benedict, Executive Vice President, Principal Accounting Officer
  • James B. Bucher J.D., Senior Vice President, General Counsel
  • Randal A. Hassler, Senior Vice President - Pharmaceutical Operations
  • John A. Latham Ph.D., Chief Scientific Officer
  • Mark James Litton Ph.D., Chief Business Officer, Treasurer and Secretary
  • Elisabeth A. Sandoval, Chief Commercial Officer
  • Jeffrey T.L. Smith M.D., Managing Director of Alder BioPharmaceuticals Limited
  • Timothy M. Whitaker M.D., Chief Medical Officer

Who owns Alder BioPharmaceuticals stock?

Alder BioPharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Quantitative Systematic Strategies LLC (0.02%). Company insiders that own Alder BioPharmaceuticals stock include Jeffrey T L Smith, John A Latham, Mark James Litton, Randall C Schatzman and Stephen M Dow. View Institutional Ownership Trends for Alder BioPharmaceuticals.

Who bought Alder BioPharmaceuticals stock? Who is buying Alder BioPharmaceuticals stock?

Alder BioPharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Quantitative Systematic Strategies LLC. View Insider Buying and Selling for Alder BioPharmaceuticals.

How do I buy Alder BioPharmaceuticals stock?

Shares of Alder BioPharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alder BioPharmaceuticals' stock price today?

One share of Alder BioPharmaceuticals stock can currently be purchased for approximately $11.50.


MarketBeat Community Rating for Alder BioPharmaceuticals (NASDAQ ALDR)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  224 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  332
MarketBeat's community ratings are surveys of what our community members think about Alder BioPharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alder BioPharmaceuticals (NASDAQ:ALDR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.91)
Consensus Price Target: $31.55 (174.31% upside)
Consensus Price Target History for Alder BioPharmaceuticals (NASDAQ:ALDR)
Price Target History for Alder BioPharmaceuticals (NASDAQ:ALDR)
Analysts' Ratings History for Alder BioPharmaceuticals (NASDAQ:ALDR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/26/2017Cowen and CompanyInitiated CoverageOutperform$20.00LowView Rating Details
9/15/2017MizuhoReiterated RatingBuy$32.00HighView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageOutperform -> Outperform$17.00HighView Rating Details
8/24/2017Credit Suisse GroupSet Price TargetHold$17.00 -> $11.00HighView Rating Details
8/10/2017Needham & Company LLCReiterated RatingBuy$36.00 -> $26.00HighView Rating Details
8/9/2017BMO Capital MarketsReiterated RatingOutperform$39.00 -> $27.00MediumView Rating Details
7/5/2017AegisReiterated RatingBuy$41.00LowView Rating Details
6/28/2017Wells Fargo & CompanyReiterated RatingOutperform$51.00HighView Rating Details
6/28/2017Piper Jaffray CompaniesReiterated RatingOverweight$47.00HighView Rating Details
6/12/2017Leerink SwannReiterated RatingOutperform$32.00MediumView Rating Details
4/17/2017Jefferies Group LLCReiterated RatingBuy$43.00LowView Rating Details
9/30/2016Brean CapitalInitiated CoverageBuy$45.00N/AView Rating Details
9/13/2016J P Morgan Chase & CoInitiated CoverageOverweight$40.00N/AView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Alder BioPharmaceuticals (NASDAQ:ALDR)
Earnings by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)
Earnings History by Quarter for Alder BioPharmaceuticals (NASDAQ ALDR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($1.67)($1.48)$0.68 millionViewListenView Earnings Details
4/27/2017Q1 2017($0.95)($1.99)ViewN/AView Earnings Details
2/23/2017Q4 2016($0.90)($0.97)ViewN/AView Earnings Details
10/27/2016Q3($0.85)($0.70)ViewListenView Earnings Details
7/26/2016Q2($0.75)($0.79)$1.14 million$0.11 millionViewListenView Earnings Details
4/28/2016Q1($0.72)($0.76)$0.14 millionViewN/AView Earnings Details
2/23/2016Q4($0.65)($0.60)ViewListenView Earnings Details
11/5/2015Q315($0.51)($0.62)$0.23 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.46)$0.23 millionViewN/AView Earnings Details
5/7/2015Q115($0.37)($0.40)ViewListenView Earnings Details
3/4/2015Q414($0.18)($0.22)$5.70 million$6.40 millionViewN/AView Earnings Details
11/3/2014Q314$0.05$0.88$14.84 million$38.75 millionViewN/AView Earnings Details
8/5/2014Q2($0.22)($0.40)$5.00 million$4.70 millionViewN/AView Earnings Details
6/20/2014Q1($0.22)($5.38)$4.60 million$4.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alder BioPharmaceuticals (NASDAQ:ALDR)
2017 EPS Consensus Estimate: ($3.89)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.98)($0.86)($0.92)
Q2 20172($1.02)($0.85)($0.94)
Q3 20172($1.06)($0.91)($0.99)
Q4 20172($1.11)($0.99)($1.05)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alder BioPharmaceuticals (NASDAQ:ALDR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Alder BioPharmaceuticals (NASDAQ:ALDR)
Insider Ownership Percentage: 10.60%
Institutional Ownership Percentage: 76.16%
Insider Trades by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)
Institutional Ownership by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)
Insider Trades by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/16/2017Mark James LittonInsiderSell16,520$12.33$203,691.60View SEC Filing  
7/18/2017Stephen M DowDirectorBuy25,000$10.00$250,000.00View SEC Filing  
6/20/2017Jeffrey T L SmithVPSell585$20.00$11,700.00View SEC Filing  
1/18/2017Mark James LittonInsiderSell1,498$23.10$34,603.80View SEC Filing  
1/9/2017Mark James LittonInsiderSell9,516$23.01$218,963.16View SEC Filing  
12/1/2016Jeffrey T. L. SmithVPSell3,000$22.78$68,340.00View SEC Filing  
12/1/2016John A. LathamInsiderSell3,636$22.78$82,828.08View SEC Filing  
11/7/2016Randall C SchatzmanCEOSell10,000$25.16$251,600.00View SEC Filing  
10/17/2016Mark James LittonInsiderSell6,000$27.50$165,000.00View SEC Filing  
10/3/2016Jeffrey T L SmithVPSell3,000$31.14$93,420.00View SEC Filing  
10/3/2016John A LathamInsiderSell10,000$31.32$313,200.00View SEC Filing  
10/3/2016Randall C SchatzmanCEOSell8,181$31.15$254,838.15View SEC Filing  
9/1/2016Jeffrey T L SmithVPSell3,000$32.49$97,470.00View SEC Filing  
9/1/2016Randall C SchatzmanInsiderSell10,000$32.48$324,800.00View SEC Filing  
8/15/2016Jeffrey T L SmithVPSell3,000$31.17$93,510.00View SEC Filing  
8/1/2016John A LathamInsiderSell10,000$31.19$311,900.00View SEC Filing  
7/27/2016John A LathamInsiderSell10,000$30.14$301,400.00View SEC Filing  
7/25/2016Randall C SchatzmanInsiderSell10,000$28.08$280,800.00View SEC Filing  
6/13/2016Mark James LittonInsiderSell6,000$28.94$173,640.00View SEC Filing  
6/3/2016Jeffrey T L SmithVPSell16,090$30.20$485,918.00View SEC Filing  
6/1/2016John A LathamInsiderSell10,000$30.02$300,200.00View SEC Filing  
5/31/2016Mark James LittonInsiderSell25,000$30.05$751,250.00View SEC Filing  
5/27/2016John A LathamInsiderSell6,401$30.05$192,350.05View SEC Filing  
5/24/2016Randall C SchatzmanCEOSell10,000$28.02$280,200.00View SEC Filing  
4/18/2016Randall C SchatzmanCEOSell30,000$28.07$842,100.00View SEC Filing  
1/4/2016Mark James LittoninsiderSell25,000$31.40$785,000.00View SEC Filing  
1/4/2016Randall C. SchatzmanCEOSell10,000$31.47$314,700.00View SEC Filing  
12/1/2015Jeffrey T. L. SmithVPSell4,272$37.24$159,089.28View SEC Filing  
12/1/2015John A. LathaminsiderSell4,550$37.24$169,442.00View SEC Filing  
12/1/2015Randall C. SchatzmanCEOSell10,000$37.24$372,400.00View SEC Filing  
11/30/2015Stephen M DowDirectorSell88$37.11$3,265.68View SEC Filing  
11/2/2015Jeffrey T. L. SmithVPSell3,900$33.67$131,313.00View SEC Filing  
11/2/2015John A. LathaminsiderSell4,545$33.69$153,121.05View SEC Filing  
11/2/2015Randall C. SchatzmanCEOSell10,000$33.71$337,100.00View SEC Filing  
10/1/2015Jeffrey T. L. SmithVPSell3,900$32.25$125,775.00View SEC Filing  
10/1/2015John A. LathaminsiderSell4,545$32.26$146,621.70View SEC Filing  
9/1/2015Jeffrey T. L. SmithVPSell3,900$38.50$150,150.00View SEC Filing  
9/1/2015John A. LathaminsiderSell4,545$38.52$175,073.40View SEC Filing  
8/31/2015Stephen M DowDirectorSell16,218$38.75$628,447.50View SEC Filing  
6/12/2015Larry BenedictVPSell25,454$47.46$1,208,046.84View SEC Filing  
6/4/2015John A LathamInsiderSell25,000$44.18$1,104,500.00View SEC Filing  
6/1/2015Jeffrey T L SmithVPSell3,900$41.53$161,967.00View SEC Filing  
6/1/2015John A LathamInsiderSell4,545$41.53$188,753.85View SEC Filing  
5/22/2015Jeffrey T L SmithVPSell61,818$38.86$2,402,247.48View SEC Filing  
5/21/2015Stephen M DowDirectorSell20,000$65.69$1,313,800.00View SEC Filing  
5/20/2015Stephen M DowDirectorSell8,462$40.39$341,780.18View SEC Filing  
5/18/2015Clay B SiegallDirectorSell38,181$37.62$1,436,369.22View SEC Filing  
4/1/2015Jeffrey T L SmithVPSell3,900$27.43$106,977.00View SEC Filing  
4/1/2015John A LathamInsiderSell19,045$29.54$562,589.30View SEC Filing  
3/30/2015John A LathamInsiderSell14,500$30.20$437,900.00View SEC Filing  
1/27/2015Jeffrey T L SmithVPSell3,900$28.01$109,239.00View SEC Filing  
1/27/2015John A LathamInsiderSell15,045$28.33$426,224.85View SEC Filing  
1/27/2015Randall C SchatzmanCEOSell100,000$28.42$2,842,000.00View SEC Filing  
1/26/2015Jeffrey T L SmithVPSell2,700$27.89$75,303.00View SEC Filing  
1/26/2015Mark James LittonInsiderSell5,200$28.03$145,756.00View SEC Filing  
1/26/2015Randall C SchatzmanCEOSell36,422$27.93$1,017,266.46View SEC Filing  
11/24/2014Jeffrey T L SmithVPSell29,090$16.08$467,767.20View SEC Filing  
5/13/2014A/S NovoInsiderBuy550,000$10.00$5,500,000.00View SEC Filing  
5/13/2014Alan Bruce MontgomeryDirectorBuy3,000$10.00$30,000.00View SEC Filing  
5/13/2014West 8 Limited Partne VenturesMajor ShareholderBuy250,000$10.00$2,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Alder BioPharmaceuticals (NASDAQ:ALDR)
Latest Headlines for Alder BioPharmaceuticals (NASDAQ:ALDR)
Source:
Loading headlines, please wait.

Social

Chart

Alder BioPharmaceuticals (ALDR) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.